{"rows":[{"id":1944,"title":"Ethical Complexities and Best Practices in Informed Consent Processes for Psilocybin Services: A Qualitative Study","normalized_title":"ethical complexities and best practices in informed consent processes for psilocybin services a qualitative study","authors":"Chwyl Christina, Bazinet Alissa, Wilson-Poe Adrianne R., Hoffman Kim, Pertl Kellie, Wolf R. Cameron, Korthuis P. Todd, Luoma Jason B.","abstract":"","journal":"Neuroethics","publication_date":"2026-07-31","publication_year":2026,"doi":"10.1007/s12152-026-09645-5","pubmed_id":null,"source_url":"https://doi.org/10.1007/s12152-026-09645-5","keywords":"","substance_tags":"psilocybin","source_name":"Crossref","date_added":"2026-07-01 06:52:05","last_checked":"2026-07-01 11:21:33","raw_json":"{\"doi\":\"10.1007/s12152-026-09645-5\",\"reference_dois\":[\"10.4103/2231-4040.116779\",\"10.2307/3564231\",\"10.1136/medethics-2020-106070\",\"10.1080/23294515.2025.2526339\",\"10.1556/2054.2023.00267\",\"10.1089/psymed.2024.0019\",\"10.1080/02791072.2025.2454474\",\"10.1046/j.1365-2702.2003.00757.x\",\"10.1111/j.1742-9544.2010.00019.x\",\"10.1016/s2215-0366(20)30146-2\",\"10.1080/15265161.2024.2433423\",\"10.1080/15265161.2024.2433428\",\"10.1080/15265161.2025.2509929\",\"10.1038/s41386-022-01389-z\",\"10.1007/s00213-011-2358-5\",\"10.1038/s41598-021-01209-2\",\"10.1093/nc/niad017\",\"10.3390/psychoactives3030026\",\"10.1007/s12152-024-09545-6\",\"10.1016/j.newideapsych.2022.100967\",\"10.1186/s13063-020-04969-w\",\"10.1002/cncr.27397\",\"10.1001/jamapsychiatry.2024.0124\",\"10.1177/02698811241257839\",\"10.29034/ijmra.v17n1a1\",\"10.1191/1478088706qp063oa\",\"10.1177/07067437231225937\",\"10.1001/jamapsychiatry.2024.0184\",\"10.1111/nup.12475\",\"10.1016/j.brat.2015.12.009\",\"10.21203/rs.3.rs-6874539/v1\",\"10.1016/j.neuropharm.2022.109165\",\"10.1080/15265161.2024.2433418\",\"10.1080/15265161.2024.2433425\",\"10.1080/15265161.2024.2433437\",\"10.1186/s40695-021-00066-3\"],\"reference_count\":53}","topic_tags":"General","study_type":"Qualitative Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":3693,"title":"Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study","normalized_title":"consciousness and psilocybin effects on well being the copewell study","authors":"University of Wisconsin, Madison","abstract":"This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why. The CoPEWell study will test whether these improvements come from the psychedelic experience itself (the \"trip\") or from direct effects on the brain. To study this, up to 120 participants will be enrolled to receive psilocybin either while awake or asleep and can expect to be on study for up to 4 months. Primary Objectives: 1. To evaluate the effect of psilocybin on wellbeing when administered while awake vs. while asleep 2. To evaluate the effect of psilocybin on wellbeing administered while asleep vs. placebo administered while asleep Secondary Objectives: 3. To evaluate the effect of psilocybin on psychological flexibility when administered while awake vs. while asleep 4. To evaluate the effect of psilocybin on psychological flexibility administered while asleep vs. placebo administered while asleep 5. To evaluate the effect of psilocybin on social connectedness when administered while awake vs. while asleep 6. To evaluate the effect of psilocybin on social connectedness administered while asleep vs. placebo administered while asleep 7. To evaluate the effect on wellbeing/life satisfaction/purpose/meaning explicitly ascribed to psilocybin administered while awake vs. while asleep 8. To evaluate the effect on wellbeing/life satisfaction/purpose/meaning explicitly ascribed to psilocybin administered while asleep vs. saline placebo administered while asleep","journal":"ClinicalTrials.gov","publication_date":"2026-07-01","publication_year":2026,"doi":null,"pubmed_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07360301","keywords":"Well-Being, Psychological, Psychedelic Experiences, Psilocybin, intravenous psilocybin, Saline Placebo, Clonidine, Clonidine ER, NOT_YET_RECRUITING","substance_tags":"psilocybin","source_name":"ClinicalTrials.gov","date_added":"2026-07-01 11:04:28","last_checked":"2026-07-02 23:06:03","raw_json":"{\"nct_id\":\"NCT07360301\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE1\"]}","topic_tags":"Consciousness,Wellbeing,Psychological Flexibility","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"clinical trial"},{"id":3972,"title":"Meskalin / Mescaline","normalized_title":"meskalin mescaline","authors":"Schüller Thomas","abstract":"# FORSCH-0351 - Meskalin / Mescaline Eigenständiges bilinguales Vollwerk (DE+EN). Transdisziplinäre wissenschaftliche Übersicht zu Meskalin entlang acht Disziplinen, mit expliziter Geltungsstufen-Kennzeichnung (gesichert / wahrscheinlich / offen). **Schwesterwerke (gleiche Struktur):** FORSCH-0291 (LSD) · FORSCH-0350 (Psilocybin) **Theorieanker:** FORSCH-0083 (ρ/δ) · **Dach:** FORSCH-0328 (Substanz-Werkfamilie) ## Was dieses Werk eigenständig macht Disziplin 8 (Recht/Gesellschaft) ist gegenüber den Schwesterwerken aufgewertet: Peyote-Artenschutz (IUCN „vulnerable\") und indigene Rechte (Native American Church, AIRFA 1994) sind hier keine Randnotiz, sondern eine eigenständige Disziplin. Im ökologisch gebundenen Fall Peyote kehrt sich gegenüber den synthetischen Stoffen (LSD/Psilocybin) das Vorzeichen der Verfügungslogik (FORSCH-0083) um. ## Kernbefund Einziger Phenethylamin-Vertreter der klassischen Psychedelika; geringste 5-HT2A-Affinität → höchste Dosis (Hunderte mg); dosisabhängige Wirkdauer 6,4-14 h. Klinik = schwächster Strang (kein adäquates RCT, Stand 2026).","journal":"Zenodo (CERN European Organization for Nuclear Research)","publication_date":"2026-06-30","publication_year":2026,"doi":"10.5281/zenodo.21113821","pubmed_id":null,"source_url":"https://doi.org/10.5281/zenodo.21113821","keywords":"Mescaline, Philosophy, Art, Humanities, Psychoanalysis, Psychology, Unconscious mind, Complement (music), Chemistry, Natural (archaeology), Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Diverse academic research themes","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-02 21:58:54","last_checked":"2026-07-02 23:03:32","raw_json":"{\"openalex_id\":\"https://openalex.org/W7166881515\",\"openalex_url\":\"https://openalex.org/W7166881515\",\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"authorships\":[{\"id\":\"https://openalex.org/A5136278242\",\"display_name\":\"Schüller Thomas\",\"orcid\":\"https://orcid.org/0009-0003-9799-6747\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4306400562\",\"source_display_name\":\"Zenodo (CERN European Organization for Nuclear Research)\",\"landing_page_url\":\"https://doi.org/10.5281/zenodo.21113821\",\"is_oa\":true}}","topic_tags":"Receptor Pharmacology,Randomized Controlled Trial,Toxicity","study_type":"Randomized Controlled Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":3971,"title":"DMT und Ayahuasca / DMT and Ayahuasca","normalized_title":"dmt und ayahuasca dmt and ayahuasca","authors":"Schüller Thomas","abstract":"DMT und Ayahuasca / DMT and Ayahuasca Eigenständiges bilinguales Vollwerk (DE+EN). Transdisziplinäre wissenschaftliche Übersicht zu DMT und Ayahuasca entlang acht Disziplinen, mit expliziter Geltungsstufen-Kennzeichnung (gesichert / wahrscheinlich / offen). **Schwesterwerke (gleiche Struktur):** FORSCH-0291 (LSD) · FORSCH-0350 (Psilocybin) · FORSCH-0351 (Meskalin) **Theorieanker:** FORSCH-0083 (ρ/δ) · **Dach:** FORSCH-0328 (Substanz-Werkfamilie) ## Was dieses Werk eigenständig macht DMT ist das vierte klassische Psychedelikum der Reihe und das erste mit diesen fünf Alleinstellungsmerkmalen: orale Unwirksamkeit ohne MAO-Hemmer; Ultrakurzwirkung (Minuten) geraucht/i.v.; Ayahuasca als Pflanzenkombination (DMT-Quelle + β-Carbolin-MAOI); endogenes Vorkommen im Säugetier; und die einzigartige Religionsrechtsprechung Gonzales v. O Centro (2006). Chemisch ist DMT ein Tryptamin (wie Psilocybin/LSD) - im Kontrast zum Phenethylamin Meskalin (0351).","journal":"Zenodo (CERN European Organization for Nuclear Research)","publication_date":"2026-06-30","publication_year":2026,"doi":"10.5281/zenodo.21113899","pubmed_id":null,"source_url":"https://doi.org/10.5281/zenodo.21113899","keywords":"Ayahuasca, Chemistry, Hallucinogen, Humanities, Philosophy, Stereochemistry, Medicine, Psychology, Traditional medicine, Art, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Libraries and Information Services","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-02 21:58:54","last_checked":"2026-07-02 23:03:32","raw_json":"{\"openalex_id\":\"https://openalex.org/W7166876974\",\"openalex_url\":\"https://openalex.org/W7166876974\",\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"authorships\":[{\"id\":\"https://openalex.org/A5136278242\",\"display_name\":\"Schüller Thomas\",\"orcid\":\"https://orcid.org/0009-0003-9799-6747\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4306400562\",\"source_display_name\":\"Zenodo (CERN European Organization for Nuclear Research)\",\"landing_page_url\":\"https://doi.org/10.5281/zenodo.21113899\",\"is_oa\":true}}","topic_tags":"Toxicity","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":3970,"title":"DMT und Ayahuasca / DMT and Ayahuasca","normalized_title":"dmt und ayahuasca dmt and ayahuasca","authors":"Schüller Thomas","abstract":"DMT und Ayahuasca / DMT and Ayahuasca Eigenständiges bilinguales Vollwerk (DE+EN). Transdisziplinäre wissenschaftliche Übersicht zu DMT und Ayahuasca entlang acht Disziplinen, mit expliziter Geltungsstufen-Kennzeichnung (gesichert / wahrscheinlich / offen). **Schwesterwerke (gleiche Struktur):** FORSCH-0291 (LSD) · FORSCH-0350 (Psilocybin) · FORSCH-0351 (Meskalin) **Theorieanker:** FORSCH-0083 (ρ/δ) · **Dach:** FORSCH-0328 (Substanz-Werkfamilie) ## Was dieses Werk eigenständig macht DMT ist das vierte klassische Psychedelikum der Reihe und das erste mit diesen fünf Alleinstellungsmerkmalen: orale Unwirksamkeit ohne MAO-Hemmer; Ultrakurzwirkung (Minuten) geraucht/i.v.; Ayahuasca als Pflanzenkombination (DMT-Quelle + β-Carbolin-MAOI); endogenes Vorkommen im Säugetier; und die einzigartige Religionsrechtsprechung Gonzales v. O Centro (2006). Chemisch ist DMT ein Tryptamin (wie Psilocybin/LSD) - im Kontrast zum Phenethylamin Meskalin (0351).","journal":"Zenodo (CERN European Organization for Nuclear Research)","publication_date":"2026-06-30","publication_year":2026,"doi":"10.5281/zenodo.21113898","pubmed_id":null,"source_url":"https://doi.org/10.5281/zenodo.21113898","keywords":"Ayahuasca, Chemistry, Hallucinogen, Humanities, Philosophy, Stereochemistry, Medicine, Psychology, Traditional medicine, Art, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Libraries and Information Services","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-02 21:58:54","last_checked":"2026-07-02 23:03:32","raw_json":"{\"openalex_id\":\"https://openalex.org/W7166860331\",\"openalex_url\":\"https://openalex.org/W7166860331\",\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"authorships\":[{\"id\":\"https://openalex.org/A5136278242\",\"display_name\":\"Schüller Thomas\",\"orcid\":\"https://orcid.org/0009-0003-9799-6747\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4306400562\",\"source_display_name\":\"Zenodo (CERN European Organization for Nuclear Research)\",\"landing_page_url\":\"https://doi.org/10.5281/zenodo.21113898\",\"is_oa\":true}}","topic_tags":"Toxicity","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":3969,"title":"Neuroestimulantes naturales: de rituales ancestrales a terapias de vanguardia","normalized_title":"neuroestimulantes naturales de rituales ancestrales a terapias de vanguardia","authors":"Armando Ordaz-Hernández, M. Corona-Ramírez, Israel Jesús Orlando Guerrero","abstract":"La psilocibina, presente en los “hongos mágicos”, y la 5-MeO-DMT, secretada por el sapo Incilius alvarius, fueron empleadas ancestralmente en rituales espirituales en México. Hoy, la ciencia las reconoce como terapias prometedoras contra depresión, ansiedad, estrés postraumático y adicciones resistentes a tratamientos convencionales. Actúan sobre receptores de serotonina y estimulan la neuroplasticidad, favoreciendo la adaptación y la superación de patrones mentales negativos. Aunque se requieren más estudios clínicos, su uso ancestral inspira terapias innovadoras que integran tradición y ciencia para mejorar el bienestar emocional (Kishon et al., 2024). Abstract Psilocybin, found in “magic mushrooms,” and 5-MeO-DMT, secreted by the Incilius alvarius toad, were ancestrally used in spiritual rituals in Mexico. Today, science recognizes them as promising therapies for depression, anxiety, post-traumatic stress disorder, and addictions resistant to conventional treatments. They act on serotonin receptors and stimulate neuroplasticity, promoting adaptation and the overcoming of negative mental patterns. Although further clinical studies are needed, their ancestral use inspires innovative therapies that integrate tradition and science to improve mental health (Kishon et al., 2024).","journal":"Revista CienciaUANL","publication_date":"2026-06-30","publication_year":2026,"doi":"10.29105/cienciauanl29.138-5","pubmed_id":null,"source_url":"https://doi.org/10.29105/cienciauanl29.138-5","keywords":"Psychology, Humanities, Mental health, Psychotherapist, Addiction, Philosophy, Medicine, Psychiatry, Clinical Practice, Sociology, Psychedelics and Drug Studies, Medical and Pharmaceutic Studies, Medicine, History, and Philosophy","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-02 21:58:54","last_checked":"2026-07-02 23:03:32","raw_json":"{\"openalex_id\":\"https://openalex.org/W7166856520\",\"openalex_url\":\"https://openalex.org/W7166856520\",\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"authorships\":[{\"id\":\"https://openalex.org/A5049625805\",\"display_name\":\"Armando Ordaz-Hernández\",\"orcid\":\"https://orcid.org/0000-0002-0197-8073\"},{\"id\":\"https://openalex.org/A5107818967\",\"display_name\":\"M. Corona-Ramírez\",\"orcid\":\"https://orcid.org/0009-0000-3928-5734\"},{\"id\":\"https://openalex.org/A5139749688\",\"display_name\":\"Israel Jesús Orlando Guerrero\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S5407047833\",\"source_display_name\":\"Revista CienciaUANL\",\"landing_page_url\":\"https://doi.org/10.29105/cienciauanl29.138-5\",\"is_oa\":true}}","topic_tags":"Depression,Anxiety,PTSD,Addiction,Neuroplasticity,Receptor Pharmacology,Spirituality","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":3968,"title":"Meskalin / Mescaline","normalized_title":"meskalin mescaline","authors":"Schüller Thomas","abstract":"# FORSCH-0351 - Meskalin / Mescaline Eigenständiges bilinguales Vollwerk (DE+EN). Transdisziplinäre wissenschaftliche Übersicht zu Meskalin entlang acht Disziplinen, mit expliziter Geltungsstufen-Kennzeichnung (gesichert / wahrscheinlich / offen). **Schwesterwerke (gleiche Struktur):** FORSCH-0291 (LSD) · FORSCH-0350 (Psilocybin) **Theorieanker:** FORSCH-0083 (ρ/δ) · **Dach:** FORSCH-0328 (Substanz-Werkfamilie) ## Was dieses Werk eigenständig macht Disziplin 8 (Recht/Gesellschaft) ist gegenüber den Schwesterwerken aufgewertet: Peyote-Artenschutz (IUCN „vulnerable\") und indigene Rechte (Native American Church, AIRFA 1994) sind hier keine Randnotiz, sondern eine eigenständige Disziplin. Im ökologisch gebundenen Fall Peyote kehrt sich gegenüber den synthetischen Stoffen (LSD/Psilocybin) das Vorzeichen der Verfügungslogik (FORSCH-0083) um. ## Kernbefund Einziger Phenethylamin-Vertreter der klassischen Psychedelika; geringste 5-HT2A-Affinität → höchste Dosis (Hunderte mg); dosisabhängige Wirkdauer 6,4-14 h. Klinik = schwächster Strang (kein adäquates RCT, Stand 2026).","journal":"Zenodo (CERN European Organization for Nuclear Research)","publication_date":"2026-06-30","publication_year":2026,"doi":"10.5281/zenodo.21113820","pubmed_id":null,"source_url":"https://doi.org/10.5281/zenodo.21113820","keywords":"Mescaline, Philosophy, Art, Humanities, Psychoanalysis, Psychology, Unconscious mind, Complement (music), Chemistry, Natural (archaeology), Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Diverse academic research themes","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-02 21:58:54","last_checked":"2026-07-02 23:03:32","raw_json":"{\"openalex_id\":\"https://openalex.org/W7166847786\",\"openalex_url\":\"https://openalex.org/W7166847786\",\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"authorships\":[{\"id\":\"https://openalex.org/A5136278242\",\"display_name\":\"Schüller Thomas\",\"orcid\":\"https://orcid.org/0009-0003-9799-6747\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4306400562\",\"source_display_name\":\"Zenodo (CERN European Organization for Nuclear Research)\",\"landing_page_url\":\"https://doi.org/10.5281/zenodo.21113820\",\"is_oa\":true}}","topic_tags":"Receptor Pharmacology,Randomized Controlled Trial,Toxicity","study_type":"Randomized Controlled Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":3967,"title":"Usos recreativos, medicinales y etnobotánicos de hongos alucinógenos: una revisión","normalized_title":"usos recreativos medicinales y etnobotánicos de hongos alucinógenos una revisión","authors":"Érika A. Chillogallo-Torres, Marcos D. Calle-Morán, Karen P. Cando-Andrade, Álex R. Morocho-Malla, E. Noemí Luzuriaga-Rodríguez","abstract":"This research involved a literature review on the recreational, Western medicinal and ethnobotanical uses of hallucinogenic mushrooms. Search engines such as PubMed and Google Scholar, among others, and Boolean operators were used. A total of 60 scientific papers in both Spanish and English were analyzed. Since the 11th century, Japan has recorded the consumption of the butterfly mushroom, Panaeolus papilionaceus, known for its hallucinogenic effects. In Mexico, the water baby mushroom, Psilocybe aztecorum, is commercially available, demonstrating its recreational use. In the United States, variability in the levels of alkaloid substances such as psilocybin and psilocin, among others, affects the recreational experience. The fly agaric mushroom, Amanita muscaria, although risky, is also used recreationally. In Ecuador, the use of the North American variegated mushroom, Panaeolus antillanum, has been reported in the Galapagos Islands. Psilocybin shows benefits in the treatment of obsessive-compulsive disorder, depression, addictions, and has anti-inflammatory effects. Furthermore, the ritual use of hallucinogenic mushrooms in Mexico, Guatemala, Peru, Asia, and other countries reinforces their historical and cultural significance. These findings highlight not only its cultural and recreational value, but also its capacity to offer new perspectives in psychological and pharmacological medicine","journal":"Multidisciplinary Collaborative Journal","publication_date":"2026-06-30","publication_year":2026,"doi":"10.70881/mcj/v4/n3/164","pubmed_id":null,"source_url":"https://doi.org/10.70881/mcj/v4/n3/164","keywords":"Psilocybin, Ethnobotany, Hallucinogen, Recreation, Traditional medicine, Recreational Drug, Geography, Tourism, Ethnology, Art, Medicine, Psychedelics and Drug Studies, Fungal Biology and Applications, Philosophy, Health, and Society","substance_tags":"psilocybin,psilocin","source_name":"OpenAlex","date_added":"2026-07-02 21:58:54","last_checked":"2026-07-02 23:03:32","raw_json":"{\"openalex_id\":\"https://openalex.org/W7166809853\",\"openalex_url\":\"https://openalex.org/W7166809853\",\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"authorships\":[{\"id\":\"https://openalex.org/A5139835780\",\"display_name\":\"Érika A. Chillogallo-Torres\",\"orcid\":\"https://orcid.org/0009-0005-0477-4403\"},{\"id\":\"https://openalex.org/A5016225646\",\"display_name\":\"Marcos D. Calle-Morán\",\"orcid\":\"https://orcid.org/0000-0001-5470-0596\"},{\"id\":\"https://openalex.org/A5139808199\",\"display_name\":\"Karen P. Cando-Andrade\",\"orcid\":\"https://orcid.org/0009-0000-5778-4684\"},{\"id\":\"https://openalex.org/A5121318772\",\"display_name\":\"Álex R. Morocho-Malla\",\"orcid\":null},{\"id\":\"https://openalex.org/A5120522194\",\"display_name\":\"E. Noemí Luzuriaga-Rodríguez\",\"orcid\":\"https://orcid.org/0009-0009-7313-9007\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S5407049083\",\"source_display_name\":\"Multidisciplinary Collaborative Journal\",\"landing_page_url\":\"https://doi.org/10.70881/mcj/v4/n3/164\",\"is_oa\":false}}","topic_tags":"Depression,Addiction,OCD,Review Article,Safety,Inflammation","study_type":"Review Article","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":3813,"title":"Convergent biosynthesis of psilocybin in an ectomycorrhizal lineage: is the psychoactive end-product the selected trait?","normalized_title":"convergent biosynthesis of psilocybin in an ectomycorrhizal lineage is the psychoactive end product the selected trait","authors":"Mellica Askari, Varun Surapaneni","abstract":"The fungivore-deterrence hypothesis, that psilocybin evolved as a chemical defence against arthropod fungivores via 5-HT receptor agonism, has become the working consensus in fungal chemical ecology, despite resting on a phylogenomic pattern of horizontal gene transfer among saprotrophs and remarkably little direct experimental evidence. Recent biochemistry shows that the ectomycorrhizal Inocybe corydalina assembles psilocybin through a convergently evolved, non-homologous ips cluster whose branched pathway yields baeocystin, not psilocybin, as the primary end-product. We argue that psilocybin's psychoactivity at vertebrate 5-HT2A receptors is plausibly incidental, with selection most likely acting on the injury-triggered polymerized indoloquinoid end-state of the blueing reaction (with psilocybin functioning as its stable storage precursor) and only secondarily on the monomeric congeners baeocystin or aeruginascin. We propose a five-tier comparative experimental program to adjudicate among these alternatives.","journal":null,"publication_date":"2026-06-30","publication_year":2026,"doi":"10.32942/x2fd49","pubmed_id":null,"source_url":"https://doi.org/10.32942/x2fd49","keywords":"Psilocybin, Biology, Convergent evolution, Vertebrate, Chemistry, Gene cluster, Adjudication, Evolutionary biology, Biochemistry, Phylogenetics, Ecology, Gene, Horizontal gene transfer, Cluster (spacecraft), Chemical defense, Cell biology, Arthropod, Psychedelics and Drug Studies, Evolutionary Game Theory and Cooperation, Chemical synthesis and alkaloids","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-02 20:31:02","last_checked":"2026-07-02 23:03:32","raw_json":"{\"openalex_id\":\"https://openalex.org/W7166796269\",\"openalex_url\":\"https://openalex.org/W7166796269\",\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"authorships\":[{\"id\":\"https://openalex.org/A5139727248\",\"display_name\":\"Mellica Askari\",\"orcid\":\"https://orcid.org/0009-0005-1876-7714\"},{\"id\":\"https://openalex.org/A5135689316\",\"display_name\":\"Varun Surapaneni\",\"orcid\":null}],\"primary_location\":{\"source_id\":null,\"source_display_name\":null,\"landing_page_url\":\"https://doi.org/10.32942/x2fd49\",\"is_oa\":true}}","topic_tags":"Mechanism of Action,Receptor Pharmacology,Genomics","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":3812,"title":"Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms","normalized_title":"past year psilocybin and alcohol co use associations with mental health symptoms","authors":"Haley M Hummel, Alexia N Obrochta, David C. R. Kerr, Anita Cservenka","abstract":"Interest has grown in the effects of psilocybin on mental health, but little is known about its naturalistic use alongside alcohol and its relationship to depression and/or anxiety symptoms. Data from the nationally-representative 2024 National Survey Investigating Hallucinogenic Trends of participants who did ( n = 1234) or did not ( n = 1607) report past-year psilocybin and alcohol co-use were compared on depressive and anxiety symptoms and poor mental health days. Weighted regressions adjusted for age, sex, survey collection period, race, ethnicity, and past-year cannabis and other psychedelic use. Individuals with psilocybin and alcohol co-use had fewer depressive symptoms ( B (SE) = −.57(.28), β = −.04, p =.043) than those who used alcohol without psilocybin, suggesting potential benefits of psilocybin in individuals with co-use. After removing cannabis and other psychedelic use covariates, psilocybin use was also related to lower anxiety symptoms. However, given the observational and self-report study design, causal inferences cannot be made. Thus, longitudinal and experimental studies are needed.","journal":"Journal of Drug Issues","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1177/00220426261466154","pubmed_id":null,"source_url":"https://doi.org/10.1177/00220426261466154","keywords":"Psilocybin, Anxiety, Hallucinogen, Psychiatry, Mental health, Cannabis, Depression (economics), Clinical psychology, Psychology, Alcohol, Observational study, Medicine, Depressive symptoms, Naturalistic observation, Substance use, Longitudinal study, Major depressive disorder, Psychedelics and Drug Studies, Forensic Toxicology and Drug Analysis, Pain Management and Placebo Effect","substance_tags":"psilocybin","source_name":"OpenAlex","date_added":"2026-07-02 06:54:51","last_checked":"2026-07-02 23:03:32","raw_json":"{\"openalex_id\":\"https://openalex.org/W7166830239\",\"openalex_url\":\"https://openalex.org/W7166830239\",\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"authorships\":[{\"id\":\"https://openalex.org/A5107648241\",\"display_name\":\"Haley M Hummel\",\"orcid\":null},{\"id\":\"https://openalex.org/A5116118092\",\"display_name\":\"Alexia N Obrochta\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139789016\",\"display_name\":\"David C. R. Kerr\",\"orcid\":null},{\"id\":\"https://openalex.org/A5088076764\",\"display_name\":\"Anita Cservenka\",\"orcid\":\"https://orcid.org/0000-0003-0813-5201\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S57770130\",\"source_display_name\":\"Journal of Drug Issues\",\"landing_page_url\":\"https://doi.org/10.1177/00220426261466154\",\"is_oa\":false}}","topic_tags":"Depression,Anxiety,Addiction,Chronic Pain,Observational Study,Toxicity","study_type":"Observational Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":3811,"title":"Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.","normalized_title":"investigating the impact of serotonergic psychedelic drugs mdma and ketamine on social cognition in psychiatric disorders a scoping review","authors":"Smith SA, Mohammad H, Lee LHN, Dennett L, Smith S, Burback L, Winkler O, Greenshaw A, Jetly R, Kennedy SH, Bhat V, Swainson J, Vermetten E, Cao B, Li XM, Zhang Y.","abstract":"RationaleInterest in psychedelic drugs has increased rapidly because of their potential therapeutic role in psychiatric disorders. Impairments in the sociocognitive skills needed to build and maintain social relationships are prominent features of many psychiatric and neurodevelopmental disorders. Emerging evidence suggests that compounds such as 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and psilocybin may influence these impairments.ObjectivesThis review aimed to determine whether psychedelic drugs may modulate social cognition in individuals with psychiatric or neurodevelopmental disorders associated with cognitive impairment.MethodsA search of the MEDLINE, PsycINFO, EMBASE, and Scopus databases was conducted. Twenty studies were identified that evaluated the effects of ketamine, MDMA, psilocybin, LSD, and ayahuasca in depressive disorders, anxiety disorders, autism spectrum disorder (ASD), and post-traumatic stress disorder (PTSD).ResultsFindings included neural activation patterns suggesting that ketamine and psilocybin may modulate processes relevant to social perception, particularly facial emotion processing, in depressive disorders. Positive findings were also reported for MDMA in participants with PTSD, including improvements in self-reported psychosocial functioning, self-awareness, and self-compassion.ConclusionsCurrent evidence suggests that psychedelic drugs may modulate processes relevant to social cognition in psychiatric disorders, although direct evidence of improved social-cognitive functioning remains limited.Clinical trial numberNot applicable.","journal":null,"publication_date":"2026-06-30","publication_year":2026,"doi":"10.1007/s00213-026-07110-y","pubmed_id":"42380668","source_url":"https://doi.org/10.1007/s00213-026-07110-y","keywords":"","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-07-01 13:00:05","last_checked":"2026-07-02 23:03:30","raw_json":"{\"europe_pmc_id\":\"42380668\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}","topic_tags":"Depression,Anxiety,PTSD,Emotional Processing,Clinical Trial,Review Article","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":3662,"title":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","normalized_title":"efficacy in relapse prevention psilocybin in alcohol use disorder with depressive symptoms","authors":"Centre Hospitalier Universitaire de Nīmes","abstract":"Up to 40% of individuals with alcohol use disorder (AUD) experience depression, which increases the risk of early relapse. Depression can cause relapse to occur 3 times faster in individuals with AUD who experience depressive symptoms at discharge. No treatments have been approved for individuals with both AUD and depression. Psilocybin, a psychedelic, shows promising results in treating both depression and addiction. It may be particularly effective for preventing relapse in people with AUD who also have depressive symptoms after detoxification, offering quicker action than traditional antidepressants. The Psilocybin Alcohol Depression (PAD) pilot study, launched in February 2024, has provided critical insights for avoiding methodological flaws and demonstrated that psilocybin-assisted psychotherapy (PAP) is both feasible and acceptable. Preliminary efficacy analyses were conducted: at 12 weeks, the 25 mg group showed significantly greater reductions in drinking days (p = 0.038) and craving frequency (p = 0.045). Relapse rates were 35% in the 25 mg group and 50% in the control group (HR = 0.52 \\[0.16-1.65\\]). In the ERPPAD trial, the study authors will compare high-dose PAP with low-dose PAP in preventing relapse in individuals with AUD and depressive symptoms. The hypothesis is that high-dose PAP will be more effective than low-dose in preventing relapse over 6 months.","journal":"ClinicalTrials.gov","publication_date":"2026-06-30","publication_year":2026,"doi":null,"pubmed_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07638553","keywords":"Alcohol Use Disorder, Depressive Sympotoms, Psilocybin, Psilocybin (high dose), Psilocybin (low dose), RECRUITING","substance_tags":"psilocybin","source_name":"ClinicalTrials.gov","date_added":"2026-07-01 11:04:28","last_checked":"2026-07-02 23:06:03","raw_json":"{\"nct_id\":\"NCT07638553\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE3\"]}","topic_tags":"Depression,Addiction,Safety","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"clinical trial"},{"id":3547,"title":"A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)","normalized_title":"a phase 2 open label study investigating the safety and efficacy of psilocybin assisted therapy for sexual assault related posttraumatic stress disorder ptsd","authors":"Sunstone Medical","abstract":"A Phase 2, Open-Label Study to explore the efficacy, safety, and tolerability of psilocybin-assisted therapy in women with sexual assault-related Posttraumatic Stress Disorder (PTSD).","journal":"ClinicalTrials.gov","publication_date":"2026-06-30","publication_year":2026,"doi":null,"pubmed_id":null,"source_url":"https://clinicaltrials.gov/study/NCT06902974","keywords":"Post Traumatic Stress Disorder, PTSD, Psilocybin 25 mg, Psilocybin-assisted therapy, RECRUITING","substance_tags":"psilocybin","source_name":"ClinicalTrials.gov","date_added":"2026-07-01 11:04:28","last_checked":"2026-07-02 23:06:03","raw_json":"{\"nct_id\":\"NCT06902974\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}","topic_tags":"PTSD,Clinical Trial,Safety","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"clinical trial"},{"id":1939,"title":"Psilocybin shows mixed results for patients with treatment-resistant depression","normalized_title":"psilocybin shows mixed results for patients with treatment resistant depression","authors":"","abstract":"Patients with treatment-resistant depression who received psilocybin-assisted psychotherapy showed clinically meaningful improvement in depressive symptoms relative to placebo, a Phase 2b trial has found. However, the study did not show a significant effect on the primary outcome of treatment response 6 weeks after the first of two doses of psilocybin. Study results were published online March 18, 2026 in JAMA Psychiatry.","journal":"The Brown University Psychopharmacology Update","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1002/pu.31461","pubmed_id":null,"source_url":"https://doi.org/10.1002/pu.31461","keywords":"","substance_tags":"psilocybin","source_name":"Crossref","date_added":"2026-07-01 06:49:23","last_checked":"2026-07-01 11:21:33","raw_json":"{\"doi\":\"10.1002/pu.31461\",\"reference_dois\":[],\"reference_count\":0}","topic_tags":"Depression,Clinical Trial,Treatment-Resistant Depression","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":1938,"title":"Single-dose psilocybin with CBT more effective than nicotine patch for smoking cessation","normalized_title":"single dose psilocybin with cbt more effective than nicotine patch for smoking cessation","authors":"","abstract":"","journal":"The Brown University Psychopharmacology Update","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1002/pu.31467","pubmed_id":null,"source_url":"https://doi.org/10.1002/pu.31467","keywords":"","substance_tags":"psilocybin","source_name":"Crossref","date_added":"2026-07-01 06:49:23","last_checked":"2026-07-01 11:21:33","raw_json":"{\"doi\":\"10.1002/pu.31467\",\"reference_dois\":[],\"reference_count\":0}","topic_tags":"Addiction","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":1920,"title":"Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review","normalized_title":"revealing shortcomings in the assessment of psilocybin effects on ocd related symptoms in preclinical and clinical studies a systematic review","authors":"Jalalian-Javadpour Marzieh, Yekta Batool Ghorbani, Reyhani Niloufar, Hajizamani Shadi, Azizi Ali, Azad Najma Khoshrooz, Mohammadi Hamidreza, Vaseghi Salar","abstract":"","journal":"Journal of Affective Disorders Reports","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1016/j.jadr.2026.101098","pubmed_id":null,"source_url":"https://doi.org/10.1016/j.jadr.2026.101098","keywords":"","substance_tags":"psilocybin","source_name":"Crossref","date_added":"2026-07-01 06:49:23","last_checked":"2026-07-02 23:03:29","raw_json":"{\"doi\":\"10.1016/j.jadr.2026.101098\",\"reference_dois\":[\"10.1007/s00213-024-06566-0\",\"10.1080/15622975.2016.1190867\",\"10.1038/s41598-020-59282-y\",\"10.1177/0269881114565144\",\"10.1038/s41380-024-02786-0\",\"10.1007/s00213-022-06286-3\",\"10.1016/s2215-0366(16)30065-7\",\"10.1097/j.pbj.0000000000000128\",\"10.3389/fpsyt.2025.1726818\",\"10.1093/ijnp/pyae057\",\"10.1001/jamapsychiatry.2020.3285\",\"10.1176/appi.ajp.2013.13040574\",\"10.1016/j.pnpbp.2005.11.005\",\"10.1016/j.neuropharm.2025.110648\",\"10.1016/j.neuropharm.2024.110202\",\"10.1037/bne0000579\",\"10.1001/archgenpsychiatry.2010.116\",\"10.3389/fpsyt.2023.1221131\",\"10.1073/pnas.2022489118\",\"10.3389/fphar.2021.640241\",\"10.1097/fbp.0000000000000757\",\"10.1192/bjo.2023.535\",\"10.1002/(sici)1096-9861(20000214)417:3<337::aid-cne7>3.0.co;2-o\",\"10.1097/fbp.0000000000000813\",\"10.1177/0269881120959614\",\"10.2139/ssrn.6218466\",\"10.1007/s00210-023-02843-5\",\"10.1016/j.heliyon.2022.e12135\",\"10.1038/s41380-023-02280-z\",\"10.1007/s00213-024-06644-3\",\"10.1371/journal.pone.0063972\",\"10.1586/14737175.9.2.255\",\"10.1192/bjo.2025.10895\",\"10.3389/fphar.2024.1391412\",\"10.1080/02791072.2020.1849879\",\"10.1016/j.celrep.2018.05.022\",\"10.3389/fpsyt.2022.1040217\",\"10.1177/02698811241269751\",\"10.1038/s41386-019-0324-9\",\"10.1177/02698811231205692\",\"10.1271/bbb.90095\",\"10.3114/fuse.2024.14.14\",\"10.1177/0269881119895520\",\"10.1177/02698811261424214\",\"10.4088/jcp.v67n1110\",\"10.1007/s00210-025-03912-7\",\"10.1016/j.pharmthera.2003.11.002\",\"10.1016/j.bbr.2020.113093\",\"10.1038/nrn3746\",\"10.1136/pgmj.57.671.543\",\"10.1016/j.comppsych.2025.152619\",\"10.1038/s41380-019-0431-3\",\"10.3389/fnbeh.2014.00180\",\"10.3390/ijms22020835\",\"10.1017/s1461145701002401\",\"10.1038/s41386-024-01794-6\",\"10.32598/bcn.2021.1920.2\",\"10.1016/j.neuron.2021.06.008\",\"10.1016/j.biopsych.2011.06.023\",\"10.1038/s41398-023-02456-9\",\"10.1038/s41572-019-0102-3\",\"10.1503/jpn.150012\",\"10.1007/s00228-024-03680-y\",\"10.1016/j.euroneuro.2013.12.006\",\"10.1016/j.jpsychires.2025.11.021\",\"10.1016/j.pnpbp.2024.111243\",\"10.1080/02791072.2014.963754\",\"10.1002/(sici)1098-2396(199709)27:1<79::aid-syn8>3.0.co;2-a\",\"10.1136/gpsych-2023-101208\",\"10.1177/02698811241249436\"],\"reference_count\":78}","topic_tags":"OCD,Systematic Review,Review Article,Animal Study","study_type":"Systematic Review","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":171,"title":"Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.","normalized_title":"blinding integrity in psychedelic randomized clinical trials a systematic review","authors":"Orsini DK, Wong S, Di Luch S, Chan B, Vasudeva S, Lovell GFM, Le GH, Jones BDM, Chisamore N, Mollica A, Johnson DE, Kaczmarek ES, Goel A, Burke MJ, Mansur R, McIntyre RS, Husain MI, Rosenblat JD.","abstract":"ImportancePsychedelic drugs possess acute psychoactive effects that can compromise blinding integrity in randomized clinical trials (RCTs). Functional unblinding, when participants or raters correctly identify treatment allocation based on subjective effects, may bias outcomes through expectancy effects, challenging the validity of efficacy estimates and regulatory acceptance.ObjectiveTo systematically quantify the prevalence of blinding integrity assessment and the extent of functional unblinding in psychedelic RCTs for psychiatric disorders.Evidence reviewA systematic review was conducted in accordance with PRISMA guidelines across OVID, MEDLINE, Embase, and APA PsycINFO (January 1, 2020, to December 11, 2025), supplemented by manual searches of 3 prior reviews for studies prior to January 2020. Eligible studies included all RCTs investigating psychedelics as psychiatric interventions. Data extracted included blinding integrity assessment methods and results for participants and raters.FindingsOf 112 RCTs (11 psilocybin, 17 lysergic acid diethylamide [LSD], 78 ketamine, 11 3,4-methylenedioxymethamphetamine [MDMA], 2 ayahuasca, 2 N,N-dimethyltryptamine [DMT], and 1 noribogaine), only 29.5% (n = 33) evaluated blinding integrity, yet 57.1% (n = 64) cited blinding as a limitation. Functional unblinding was substantial: psilocybin, LSD, and ayahuasca studies frequently reported blinding failure values of more than 90% among participants and raters, inert placebo-controlled MDMA trials exceeded 85%, and ketamine trials rarely assessed blinding (17.9%) but showed improved preservation with midazolam vs saline controls. No control strategy consistently achieved ideal blinding.Conclusions and relevanceThis first evaluation of blinding integrity in psychedelic RCTs indicates functional unblinding is pervasive among participants and raters raising concerns about the validity of efficacy findings. Few trials assess blinding or expectancy, highlighting the need for standardized, validated measures and innovative designs to separate true pharmacological effects from expectancy-driven responses.","journal":null,"publication_date":"2026-06-30","publication_year":2026,"doi":"10.1001/jamapsychiatry.2026.0255","pubmed_id":"41984443","source_url":"https://doi.org/10.1001/jamapsychiatry.2026.0255","keywords":"Humans, Hallucinogens, Mental Disorders, Randomized Controlled Trials as Topic","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-02 23:03:30","raw_json":"{\"europe_pmc_id\":\"41984443\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}","topic_tags":"Clinical Trial,Randomized Controlled Trial,Systematic Review,Review Article","study_type":"Randomized Controlled Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":107,"title":"Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.","normalized_title":"implementing psilocybin assisted therapy in palliative care settings a survey of stakeholders","authors":"Plourde L, Chang SL, Nguyen O, Garel N, Farzin H, Stephan JF, Fallu JS, Dorval M, P3A Research Group","abstract":"While the adoption of psilocybin-assisted therapy for existential distress offers promising support for patients with life-threatening illnesses, implementing this intervention into palliative care settings presents significant real-world challenges. To examine palliative care stakeholders' knowledge and attitudes regarding psilocybin-assisted therapy, and identify barriers and facilitators to its implementation. We conducted a cross-sectional online survey between April 15 and December 18, 2024. The survey assessed perceived knowledge, attitudes, and perceived barriers and facilitators to the effective integration of psilocybin-assisted therapy into palliative care settings. One hundred and twenty-one adults involved in palliative care (physicians, other healthcare professionals, caregivers, and managers) were recruited from Canada's four most populous provinces: Québec, Ontario, Alberta, and British Columbia. Forty-three percent of stakeholders reported having good knowledge of psilocybin's potential benefits and risks. Attitudes towards psilocybin-assisted therapy were predominantly non-favourable (61%), yet varied across occupational groups ( Translating the potential of psilocybin-assisted therapy for existential distress from clinical trials into palliative care settings requires careful consideration and collaboration with stakeholders. Given the significant divergence in perspectives between clinical and non-clinical groups, tailored interprofessional education could help build shared understanding and support effective implementation. Being conducted in Canada, transferability to different regulatory frameworks may be limited.","journal":"Palliative medicine","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1177/02692163261446141","pubmed_id":"42154482","source_url":"https://pubmed.ncbi.nlm.nih.gov/42154482/","keywords":"attitude of health personnel, hallucinogens, palliative care, psilocybin, surveys and questionnaires","substance_tags":"psilocybin","source_name":"PubMed","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-02 23:03:18","raw_json":"{\"pubmed_id\":\"42154482\"}","topic_tags":"End-of-Life Distress,Clinical Trial,Observational Study,Safety","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":58,"title":"MFCC-DFT mapping of ligand recognition at the 5-HT2A receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.","normalized_title":"mfcc dft mapping of ligand recognition at the 5 ht2a receptor energetic analysis of the interactions between serotonin psychedelics and antipsychotics","authors":"Junior WSC, Bezerra KS, Matias EGC, Oliveira JIN, Fulco UL.","abstract":"Mental disorders represent a major global health problem, with depression being one of the most prevalent and disabling conditions worldwide. Growing evidence suggests that the serotonergic system, particularly the 5-HT2A receptor, plays an important role in modulating mood and cognitive processes, constituting a key pharmacological target for several psychoactive compounds. In this study, we investigated the molecular interaction profile between the 5-HT2A receptor and four pharmacologically relevant ligands, serotonin (5-HT), psilocybin/psilocin (PSILO), lysergic acid diethylamide (LSD), and lumateperone (LMTP). Interaction energies were evaluated using the molecular fragmentation with conjugated caps (MFCC) method combined with density functional theory (DFT) calculations. Crystallographic structures were used as initial models, and residue-level interaction energies were calculated to identify the amino acids that contribute most to ligand stabilization at the receptor binding site. The results reveal that the complexes exhibit total interaction energies ranging from -35.38 to -71.98 kcal mol-1 under dielectric conditions representative of the protein environment. Key residues such as Asp155, Phe339, Leu229, and Val366 were identified as the main contributors to ligand stabilization in the studied systems, highlighting their role as structural anchors within the orthosteric binding pocket. Energy decomposition further revealed distinct interaction patterns associated with different regions of the ligand. Therefore, this study provides a detailed energetic characterization of ligand recognition in the 5-HT2A receptor and offers details that may contribute to the rational design of new serotonergic agents with potential for therapeutic applications.","journal":null,"publication_date":"2026-06-30","publication_year":2026,"doi":"10.1039/d6cp00943c","pubmed_id":"42300394","source_url":"https://doi.org/10.1039/d6cp00943c","keywords":"Humans, Serotonin, Lysergic Acid Diethylamide, Receptor, Serotonin, 5-HT2A, Antipsychotic Agents, Hallucinogens, Ligands, Binding Sites, Thermodynamics, Psilocybin, Heterocyclic Compounds, 4 or More Rings, Density Functional Theory","substance_tags":"psilocybin,psilocin","source_name":"Europe PMC","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-02 23:03:30","raw_json":"{\"europe_pmc_id\":\"42300394\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}","topic_tags":"Depression,Receptor Pharmacology,Drug Interactions","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"},{"id":21,"title":"Chemistry/structural biology of psychedelic drugs and their receptor(s).","normalized_title":"chemistry structural biology of psychedelic drugs and their receptor s","authors":"Gumpper RH, Nichols DE","abstract":"This brief review highlights some of the structure-activity relationships of classic serotonergic psychedelics. In particular, we discuss structural features of three chemotypes: phenethylamines, ergolines and certain tryptamines, which possess psychedelic activity in humans. Where they are known, we point out the underlying molecular mechanisms utilized by each of the three chemotypes of psychedelic molecules. With a focus on the 5-HT receptor subtype, a G-protein coupled receptor known to be the primary target of psychedelics, we refer to several X-ray and cryoEM structures, with a variety of ligands bound, to illustrate the underlying atomistic basis for some of the known pharmacological observations of psychedelic drug actions. LINKED ARTICLES: This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc.","journal":"British journal of pharmacology","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1111/bph.17361","pubmed_id":"39354889","source_url":"https://pubmed.ncbi.nlm.nih.gov/39354889/","keywords":"5-HT2A agonists, 5-HT2A receptor, LSD, Psychedelic chemotypes, crystal structures, docking, ergolines, phenethylamines, psilocybin, structural biology, structure-activity relationships, therapeutic potential, tryptamines","substance_tags":"psilocybin","source_name":"PubMed","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-02 23:03:18","raw_json":"{\"pubmed_id\":\"39354889\"}","topic_tags":"Mechanism of Action,Receptor Pharmacology,Review Article","study_type":"Review Article","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published"}],"total":3974,"page":1,"per_page":20,"pages":199,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"sources":[],"publication_statuses":[],"year":null,"journal":null,"from":null,"to":null,"sort":"newest","page":1,"per_page":"20"}}